Montag, 6. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
LYMPH

The LYMPH Trial - Surgical Versus Conservative Complex Physical Decongestion Therapy for Chronic Breast Cancer-Related Lymphedema

Rekrutierend

NCT-Nummer:
NCT05890677

Studienbeginn:
Juli 2023

Letztes Update:
08.03.2024

Wirkstoff:
-

Indikation (Clinical Trials):
Breast Neoplasms, Lymphedema, Breast Cancer Lymphedema

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
University Hospital, Basel, Switzerland

Collaborator:
Swiss National Science Foundation, Rising Tide Foundation, Krebsforschung Schweiz, Bern, Switzerland,

Studienleiter

Elisabeth Kappos, PD Dr. med.
Principal Investigator
University Hospital, Basel, Switzerland

Kontakt

Studienlocations
(3 von 31)

Sana Kliniken Düsseldorf
40593 Düsseldorf
(Nordrhein-Westfalen)
GermanyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Katrin Seidenstücker, Dr.
Phone: +49 211 2800 1990
E-Mail: katrin.seidenstuecker@sana.de
» Ansprechpartner anzeigen
KEM Evang. Kliniken Essen-Mitte
45136 Essen
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Björn Behr, Prof. Dr. med.
Phone: +49 234 302 7152
E-Mail: transchirurgie-zentrum@kem-med.com


Phone: +49 201 174 29006
E-Mail: bjorn.behr@rub.de
» Ansprechpartner anzeigen
BG Klinik Frankfurt am Main
60389 Frankfurt
(Hessen)
GermanyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Christoph Hirche, Prof. Dr. med.
Phone: +49 69 475 23 23
E-Mail: ulrich.kneser@bgu-ludwigshafen.de
» Ansprechpartner anzeigen
Universitätsklinikum Freiburg, Klinik für Plastische und Handchirurgie
79106 Freiburg im Breisgau
(Baden-Württemberg)
GermanyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Steffen Eisenhardt, Prof. Dr. med.
Phone: +49 761 270 28170
E-Mail: steffen.eisenhardt@uniklinik-freiburg.de


E-Mail: bianca.kremer@uniklinik-freiburg.de
» Ansprechpartner anzeigen
Universitätsklinikum Göttingen
37075 Göttingen
(Niedersachsen)
GermanyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Gunther Felmerer, Prof. Dr. Med.
Phone: 0551 / 39 - 65422
E-Mail: plastische.chirurgie@med.uni-goettingen.de
» Ansprechpartner anzeigen
BG Klinik Ludwigshafen
67071 Ludwigshafen am Rhein
(Rheinland-Pfalz)
GermanyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Ulrich Kneser, Prof. Dr. med.
Phone: +49 621 681 023 28
E-Mail: ulrich.kneser@bgu-ludwigshafen.de
» Ansprechpartner anzeigen
Caritas Krankenhaus St. Josef/ Uniklinik Regensburg
93053 Regensburg
(Bayern)
GermanyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Lukas Prantl, Prof. Dr. med.
Phone: +49 941 944 6763
E-Mail: Lukas.Prantl@klinik.uni-regensburg.de

Norbert Heine, Dr. med.
» Ansprechpartner anzeigen
Harvard Medical School
02115 Boston
United StatesNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Andrea Pusic, Prof. Dr. med.
Phone: +16 17 732 53 61
E-Mail: apusic@bwh.harvard.edu

Erin Taylor, Dr. med.
» Ansprechpartner anzeigen
Washington University School of Medicine in St. Louis
63110 Saint Louis
United StatesNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Justin M. Sacks, Prof. Dr.
Phone: 314-454-4894
E-Mail: jmsacks@wustl.edu
» Ansprechpartner anzeigen
Universidad de Buenos Aires, Instituto de Oncología Ángel H. Roffo
C1417 Buenos Aires
ArgentinaNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Eduardo Gonzalez, Dr. med.
Phone: +54 11 15 5180 4224
E-Mail: egonzalez57@hotmail.com


E-Mail: edugonzalez57@gmail.com
» Ansprechpartner anzeigen
Klinikum Klagenfurt
9020 Klagenfurt
AustriaNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Madeleine Mischitz, Dr.
Phone: 0043 463 538 22970
E-Mail: Madeleine.Mischitz@kabeg.at

Matthias Rab, Dr.
» Ansprechpartner anzeigen
McGill University, Royal Victoria Hospital
QC H4A 3J1 Montreal
CanadaNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Josh Vorstenbosch, MD PhD FRCSC
Phone: +1(514)934-1934 x 35194
E-Mail: joshua.vorstenbosch@mcgill.ca

Anna Towers, Dr.
» Ansprechpartner anzeigen
University of British Columbia, Gordon and Leslie Diamond Health Care Centre
BC V5Z 1M9 Vancouver
CanadaNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Kathryn V. Isaac, Asst. Prof. Dr.
Phone: +1 604-336-9488
E-Mail: kathryn.isaac@ubc.ca
» Ansprechpartner anzeigen
Papageorgiou Hospital of Thessaloniki
55133 Thessaloníki
GreeceNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Efterpi Demiri, Prof. Dr. med.
Phone: +30 231 332 38 38
E-Mail: demirie@auth.gr

Dimitrios Dionysiou, Dr. med.
» Ansprechpartner anzeigen
Plastic and Reconstructive Surgery at Department of Surgical Science
00133 Rome
ItalyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Benedetto Longo, Dr. med.
Phone: +39 6 44291148
E-Mail: benedetto.longo@uniroma2.it


E-Mail: info@benedettolongo.com
» Ansprechpartner anzeigen
Policlinic Gemelli, Operational Unit of Plastic Surgery
00168 Rome
ItalyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Giuseppe Visconti, Dr. med.
Phone: +39 06 30151
E-Mail: giuseppe.visconti@policlinicogemelli.it
» Ansprechpartner anzeigen
Maastricht University Medical Center
6202 Maastricht
NetherlandsNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Shao Shan Qiu, Dr.
Phone: +31(0)43-3877481
E-Mail: shanshan.qiushao@mumc.nl
» Ansprechpartner anzeigen
Institute of Oncology ''Prof. Dr. Ion Chiricuță'' of Cluj-Napoca
400015 Cluj-Napoca
RomaniaRekrutierend» Google-Maps
Ansprechpartner:
Maximilian Vlad Muntean, Dr. med.
Phone: +40 730085422
E-Mail: maximilian.muntean@gmail.com
» Ansprechpartner anzeigen
Karolinska Institutet, K1 Molekylär medicin och kirurgi
17176 Stockholm
SwedenNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Martin Halle, Dr. med.
Phone: +46 8 123 708 46
E-Mail: martin.halle@ki.se
» Ansprechpartner anzeigen
Department of Plastic and Reconstructive Surgery Uppsala University Hospital
751 85 Uppsala
SwedenNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Maria Mani, Dr. med.
E-Mail: Maria.Mani@surgsci.uu.se
» Ansprechpartner anzeigen
Hôpitaux Universitaires de Genève
1205 Genève
SwitzerlandNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Daniel Kalbermatten, Prof. Dr. med.
Phone: +41 22 372 80 12
E-Mail: daniel.kalbermatten@hcuge.ch
» Ansprechpartner anzeigen
Centre Hospitalier Universitaire Vaudois
1011 Lausanne
SwitzerlandNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Pietro di Summa, PD Dr. med.
Phone: +41 21 314 25 25
E-Mail: pietro.di-summa@chuv.ch
» Ansprechpartner anzeigen
Klinik für Plastische, Rekonstruktive, Aesthetische und Handchirurgie
8091 Zürich
SwitzerlandRekrutierend» Google-Maps
Ansprechpartner:
Nicole Lindenblatt, Prof. Dr. med.
Phone: +41 44 255 11 11
E-Mail: nicole.lindenblatt@usz.ch
» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Detailed Description:

To date, conservative complex physical decongestion therapy (CDT) is the gold standard for

BCRL (breast cancer related lymphedema) and includes manual lymphatic drainage, local

compression with bandages and garments, physical exercises and meticulous skin care. It is,

however, too often ineffective to prevent stage progression in curing BCRL and purely

symptomatic. Lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT) are

two surgical techniques that, in contrast to CDT, are able to actually address the underlying

causes and eventually restore the lymphatic drainage. LVA achieves this by creating numerous

bypasses between lymphatic vessels and venules allowing the drainage of excessive fluid

within the subcutaneous tissues into the venous system, while VLNT usually brings functioning

lymph nodes to an area devoid of lymph nodes or with dysfunctional lymph nodes, thus enabling

the spontaneous development of new lymphatic pathways. Both techniques have shown very

promising results with low complication rates and improved Quality of Life (QoL) for the

patients. However, no multicentric randomized controlled trial (RCT) has yet prospectively

evaluated the superiority of these surgical techniques over CDT alone, limiting patient's

access to most effective treatment available. Requests for cost reimbursement must still be

submitted to insurance companies in most countries and are often rejected, thus delaying

surgical treatment and resulting in prolonged suffering of affected patients. This is

untenable seeing as affected patients suffer from a heavy physical, psychological and

financial burden. This pragmatic, randomized, multicenter trial aims to establish a solid

scientific basis assessing the superiority of surgical treatment over CDT alone.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Written informed consent.

- Patients ≥ 18 years of age with prior treatment of breast cancer.

- At least one of the following prior breast cancer treatments: sentinel lymph node

biopsy (SLNB), axillary lymph node dissection (ALND), radiotherapy (RT) of chest wall

or axilla or breast cancer surgery.

- Clinical diagnosis of chronic BCRL as defined by the ISL (inter-limb difference of

>10% in volume or excess volume between the affected and non-affected limbs present

for more than 3 months).

- Minimum of 3 months CDT.

- Ability to complete the QoL questionnaires.

Exclusion Criteria:

- No indication for lymphatic surgery according to clinical judgment of the treating

surgeon (individual reasons will be specifically documented).

- Primary congenital LE or non-breast cancer-related LE.

- Need for immediate LE surgery according to clinical judgement by a specialist due to

far progressed LE stage.

Studien-Rationale

Primary outcome:

1. Change in Quality of Life Questionnaire (Lymph-ICF-UL) (Time Frame - two time assessment at baseline and 15 month after randomization):
One of the most widely used PRO (patient reported outcome) instruments in chronic BCRL (breast cancer related lymphedema) is the LYMPH-ICF-UL-Questionnaire (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema), a rigorously developed and validated PRO instrument specific to BCRL. This questionnaire assesses the impairments in function, activity limitations and participation restrictions of patients with upper LE (limb lymphedema). It is a validated questionnaire, consisting of 29 items (questions) across five different domains. Each item is scored on a VAS (visual analog scale) ranging from 0 to 10. The total score on the LYMPH-ICF is equal to the sum of the item scores divided by the total number of answered items. A higher score on the Lymph-ICF indicates a greater impact on the functioning in daily life related to upper limb LE.



Secondary outcome:

1. Change in Quality of Life Questionnaire (Lymph-ICF-UL) (Time Frame - 13 time assessment up to 10 years after randomization):
One of the most widely used PRO (patient reported outcome) instruments in chronic BCRL (breast cancer related lymphedema) is the LYMPH-ICF-UL-Questionnaire (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema), a rigorously developed and validated PRO instrument specific to BCRL. This questionnaire assesses the impairments in function, activity limitations and participation restrictions of patients with upper LE (limb lymphedema). It is a validated questionnaire, consisting of 29 items (questions) across five different domains. Each item is scored on a VAS (visual analog scale) ranging from 0 to 10. The total score on the LYMPH-ICF is equal to the sum of the item scores divided by the total number of answered items. A higher score on the Lymph-ICF indicates a greater impact on the functioning in daily life related to upper limb LE.

2. Change in Quality of Life Questionnaire (LYMPH-Q) (Time Frame - 15 time assessment up to 10 years after randomization):
The Lymph-Q Upper Extremity Module is a new PROM (patient-reported outcome measure) developed to assess patient reported outcomes of BCRL in a concept-driven approach. The complete questionnaire contains 68 questions covering the patient-relevant topics Health-related quality of life (arm appearance, arm function, arm symptoms, psychological), experience of care (information), and treatment (arm sleeve).

3. Change in Quality of Life Questionnaire (EuroQol EQ-5D-5L) (Time Frame - 15 time assessment up to 10 years after randomization):
The 5-level EQ-5D version (EQ-5D-5L) consists of the EQ-5D descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions (5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems) resulting in a 1-digit number that expresses the level for that dimension. The digits for each dimension can be combined into a 5-digit number that describes the patient's health state.

4. Change in Pain score (visual analog scale) (Time Frame - 7 time assessment up to 1 year):
The pain score consists of a VAS (visual analog scale) ranging from 0 (i.e. no pain) to 10 (i.e. worst pain). The VAS was published by the Yale University

Studien-Arme

  • Experimental: Group A : Surgical Group
    According to the pragmatic study design, neither the diagnostic workup nor the surgery will be standardized in order to offer surgeons considerable leeway on how to perform lymphatic surgery, which resembles the flexibility in usual care. The key aspects of the preoperative workup and the surgery including the number of LVAs (Lymphovenous Anastomosis), harvesting of lymph nodes ("donor site"), time of surgery, and practical details will be registered.
  • Active Comparator: Group B: Conservative Complex Physical Decongestion Therapy (control group)
    CDT (Conservative Complex Physical Decongestion Therapy) will be performed as in usual care, following the pragmatic study design. The key aspects like frequency of lymphatic drainage, time when lymphatic drainage is performed and time and class of compressive garments are used will be documented. CDT incorporates two stages of treatment. The first treatment phase (intensive phase) entails skincare, MLD (manual lymphatic drainage), exercises aimed at improvement of mobility/range of motion in the shoulder, elbow or wrist joints, and compression therapy through bandaging. Most patients undergo this phase shortly after the diagnosis of LE. CDT in the second phase (maintenance phase) aims to maintain the achieved limb volume/ circumference reduction through compression with therapeutic elastic compression garment for the arm. Skincare, mobility exercises and MLD is continued in this phase if needed

Geprüfte Regime

  • Surgical Intervention:
    LVA (Lymphovenous Anastomosis) and VLNT (Vascularised Lymph Node Transfer) are two advanced microsurgical techniques that are increasingly implemented in clinical practice in specialized centers and that are already carried out after health insurance application according to local standard of care. They have been studied in their respective mode of action as well as in their effectiveness in treating chronic BCRL (Breast Cancer-Related Lymphedema) in a multitude of mostly observational and single center studies with highly encouraging results. Patients in the interventional arm A will receive surgery with one of the two approaches or a combination of both, in a one or two-stage method, at the discretion of the treating surgeon. Depending on local standards one or both of the above might be combined with liposuction to the affected arm in a one or two-stage approach as well.
  • Conservative Complex Physical Decongestion Therapy:
    Patients randomized to the control arm will receive CDT (Conservative Complex Physical Decongestion Therapy), which currently is considered as the best available standard of care. For this, patients will be referred to one of the dedicated LE (physical/skin) therapy clinics, if not already treated by one, according to their place of residence for continuation of standard conservative therapy. Recommendations to the procedures and treatment frequency of the conservative therapy will be made, but CDT will be done at the discretion of the treating physiotherapist.

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"The LYMPH Trial - Surgical Versus Conservative Complex Physical Decongestion Therapy for Chronic Breast Cancer-Related Lymphedema"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.